May 19, 2020
NIH begins clinical trial of hydroxychloroquine, azithromycin for COVID-19 treatment
Editor's Note
The National Institutes of Health (NIH) on May 14 announced that it is enrolling adults with mild to moderate COVID-19 in a study of treatment with hydroxychloroquine and azithromycin.
The Phase 2b trial is enrolling around 2,000 adults across the US. Participants must have confirmed infection with SARS-CoV-2 and be experiencing fever, cough, and/or shortness of breath.
The participants will be randomly assigned to short-term treatment with either hydroxychloroquine and azithromycin or matching placebos.
Free Daily News
- HHS report highlights cost, access, quality concerns with private equity in healthcare
- Study: Racial, gender disparities persist in bariatric surgery
- Study: Dry eye risks complicate cataract surgery recovery
- Study: Observational learning ineffective in ensuring nursing student infection control compliance
- Students innovate to reduce OR plastic waste
- OR Business Management Conference 2025 features fresh perspectives, new tracks
- Survey: Bariatric surgery’s fertility benefits not widely understood
- Study highlights nurse staffing disparity in hospitals serving black populations
- Joint Commission issues new workplace violence prevention standards
- AI outperforms experts in ovarian cancer ultrasound detection
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement